MX381544B - Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto. - Google Patents
Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.Info
- Publication number
- MX381544B MX381544B MX2017000142A MX2017000142A MX381544B MX 381544 B MX381544 B MX 381544B MX 2017000142 A MX2017000142 A MX 2017000142A MX 2017000142 A MX2017000142 A MX 2017000142A MX 381544 B MX381544 B MX 381544B
- Authority
- MX
- Mexico
- Prior art keywords
- sepsis
- subject
- treatment
- composition
- stroma cells
- Prior art date
Links
- 206010040047 Sepsis Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000002536 stromal cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14175095 | 2014-06-30 | ||
| PCT/IB2015/054923 WO2016001846A1 (en) | 2014-06-30 | 2015-06-30 | Mesenchymal stromal cells for treating sepsis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017000142A MX2017000142A (es) | 2017-07-28 |
| MX381544B true MX381544B (es) | 2025-03-12 |
Family
ID=51033023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000142A MX381544B (es) | 2014-06-30 | 2015-06-30 | Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20170151284A1 (enExample) |
| EP (1) | EP3160481B1 (enExample) |
| JP (1) | JP6722599B2 (enExample) |
| KR (1) | KR102213527B1 (enExample) |
| CN (1) | CN106573017B (enExample) |
| AU (1) | AU2015283662B2 (enExample) |
| BR (1) | BR112016030758B8 (enExample) |
| CA (1) | CA2953884C (enExample) |
| IL (1) | IL249814B (enExample) |
| MX (1) | MX381544B (enExample) |
| NZ (1) | NZ727950A (enExample) |
| RU (1) | RU2715866C2 (enExample) |
| SG (1) | SG11201610844PA (enExample) |
| WO (1) | WO2016001846A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6714932B2 (ja) * | 2015-12-01 | 2020-07-01 | 株式会社ＡｄｉｐｏＳｅｅｄｓ | 脊椎動物の脂肪組織由来間葉系細胞株の製造方法 |
| US11701389B2 (en) | 2016-03-09 | 2023-07-18 | Emory University | Methods of preserving mesenchymal stem cells |
| GB201604304D0 (en) * | 2016-03-14 | 2016-04-27 | Tigenix S A U | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
| CN110520138A (zh) | 2017-02-28 | 2019-11-29 | 洛林大学 | 从华顿氏胶获得的用于治疗脓毒症的间充质干细胞 |
| US11524000B2 (en) | 2017-10-26 | 2022-12-13 | Emory University | Targeting Mcl-1 to enhance DNA replication stress sensitivity for cancer therapy |
| KR20250160527A (ko) * | 2018-06-05 | 2025-11-13 | 메디포스트(주) | 히알루론산과 줄기세포를 포함하는 연골손상 관련 질환 치료용 약학 조성물 |
| ES2962812T3 (es) * | 2018-10-29 | 2024-03-21 | Ottawa Hospital Res Inst | Células madre mesenquimatosas modificadas genéticamente que sobreexpresan AOAH y sus usos |
| EP4098267A4 (en) * | 2020-01-30 | 2024-03-06 | JCR Pharmaceuticals Co., Ltd. | MEDICINAL COMPOSITION COMPRISING CELLS DERIVED FROM DENTAL PULP |
| US20240226173A1 (en) * | 2021-05-13 | 2024-07-11 | Primegen Us, Inc. | Methods and compositions for treating liver disease |
| CN113398150A (zh) * | 2021-06-18 | 2021-09-17 | 卡替(上海)生物技术有限公司 | 牙髓间充质干细胞在脓毒症治疗中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9307550A (pt) | 1992-12-02 | 1999-05-25 | Shell Int Research | Composto fungicida processo para a preparação de um composto fungicida composição fungicida processo de combate aos fungos em um local e uso |
| WO1995002698A1 (en) | 1993-07-12 | 1995-01-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
| EP0832271B8 (en) | 1995-06-07 | 2005-03-02 | INEX Pharmaceuticals Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| US5705308A (en) | 1996-09-30 | 1998-01-06 | Eastman Kodak Company | Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element |
| US6777231B1 (en) | 1999-03-10 | 2004-08-17 | The Regents Of The University Of California | Adipose-derived stem cells and lattices |
| EP2298863B1 (en) * | 2004-03-22 | 2015-07-22 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
| JP5925408B2 (ja) | 2005-09-23 | 2016-05-25 | タイジェニックス、ソシエダッド、アノニマ、ウニペルソナルＴｉｇｅｎｉｘ Ｓ．Ａ．Ｕ． | 免疫調節活性を有する細胞集団、単離方法および使用 |
| GB0814249D0 (en) * | 2008-08-04 | 2008-09-10 | Cellerix Sa | Uses of mesenchymal stem cells |
| CN109432126B (zh) * | 2011-03-11 | 2022-06-14 | 儿童医学中心公司 | 与间充质干细胞外来体相关的方法和组合物 |
| JP2014016782A (ja) * | 2012-07-09 | 2014-01-30 | Toshiba Corp | 情報処理装置およびプログラム |
| US20140134140A1 (en) * | 2012-11-09 | 2014-05-15 | Case Western Reserve University | Mesenchymal stem cell compositions for the treatment of microbial infections |
-
2015
- 2015-06-30 CA CA2953884A patent/CA2953884C/en active Active
- 2015-06-30 AU AU2015283662A patent/AU2015283662B2/en active Active
- 2015-06-30 BR BR112016030758A patent/BR112016030758B8/pt active IP Right Grant
- 2015-06-30 JP JP2016575950A patent/JP6722599B2/ja active Active
- 2015-06-30 US US15/323,373 patent/US20170151284A1/en not_active Abandoned
- 2015-06-30 NZ NZ727950A patent/NZ727950A/en unknown
- 2015-06-30 RU RU2016151738A patent/RU2715866C2/ru active
- 2015-06-30 SG SG11201610844PA patent/SG11201610844PA/en unknown
- 2015-06-30 MX MX2017000142A patent/MX381544B/es unknown
- 2015-06-30 KR KR1020177002380A patent/KR102213527B1/ko active Active
- 2015-06-30 WO PCT/IB2015/054923 patent/WO2016001846A1/en not_active Ceased
- 2015-06-30 CN CN201580042833.7A patent/CN106573017B/zh active Active
- 2015-06-30 EP EP15742102.5A patent/EP3160481B1/en active Active
-
2016
- 2016-12-28 IL IL249814A patent/IL249814B/en active IP Right Grant
-
2020
- 2020-08-14 US US16/994,379 patent/US20200376038A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200376038A1 (en) | 2020-12-03 |
| RU2016151738A3 (enExample) | 2019-01-30 |
| US20170151284A1 (en) | 2017-06-01 |
| BR112016030758A2 (enExample) | 2017-08-22 |
| BR112016030758B8 (pt) | 2022-10-25 |
| IL249814A0 (en) | 2017-03-30 |
| IL249814B (en) | 2020-02-27 |
| JP6722599B2 (ja) | 2020-07-15 |
| MX2017000142A (es) | 2017-07-28 |
| EP3160481B1 (en) | 2020-09-09 |
| CA2953884C (en) | 2022-12-06 |
| AU2015283662B2 (en) | 2020-09-24 |
| CN106573017B (zh) | 2021-06-11 |
| RU2715866C2 (ru) | 2020-03-03 |
| WO2016001846A1 (en) | 2016-01-07 |
| EP3160481A1 (en) | 2017-05-03 |
| KR102213527B1 (ko) | 2021-02-09 |
| CN106573017A (zh) | 2017-04-19 |
| RU2016151738A (ru) | 2018-07-30 |
| KR20170021343A (ko) | 2017-02-27 |
| AU2015283662A1 (en) | 2017-01-19 |
| SG11201610844PA (en) | 2017-01-27 |
| JP2017520583A (ja) | 2017-07-27 |
| NZ727950A (en) | 2022-07-01 |
| CA2953884A1 (en) | 2016-01-07 |
| BR112016030758B1 (pt) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| MX381544B (es) | Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto. | |
| MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
| EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| SA517381769B1 (ar) | توليد حمض بيروكسي فورميك من خلال فورمات كحول بولي هيدريك | |
| AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| EA201891251A1 (ru) | Бициклические ингибиторы pad4 | |
| CL2016001840A1 (es) | Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer. | |
| UY34201A (es) | Compuestos de azaindol y métodos para el tratamiento de vih. | |
| EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| CY1122264T1 (el) | Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| EA201891347A1 (ru) | Аза-бензимидазольные ингибиторы pad4 | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| EA201790461A1 (ru) | Композиции внеклеточного матрикса | |
| DK3204038T3 (da) | Sammensætninger omfattende amylase til anvendelse i behandlingen af pruritus | |
| MX374385B (es) | Apilimod para uso en el tratamiento de melanoma. | |
| MX2017003953A (es) | Compuestos que contrarrestan el mal olor bajo, de cobertura-alta y metodos uso. | |
| BR112018008931A2 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
| BR112017009289A2 (pt) | métodos de administrar composições de amantadina | |
| MX384131B (es) | Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos. |